BIO-BRIDGE SIGNS DISTRIBUTION PACT WITH XINHUA SURGICAL.Bio-Bridge Science, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : BGES),Oak Brook, Ill., has entered into an exclusive distribution agreement with Xinhua Surgical Instruments Co., Ltd., located in Shandong, China. Under the agreement, Bio-Bridge Science has been granted exclusive distribution rights for all Xinhua surgical instruments in the United States, which are subject to FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval. About Xinhua Xinhua Surgical Instruments Co. Ltd. is a world leader in surgical instrument production that is based in Shandong, China. Dr. Liang Qiao, chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bio-Bridge Science said, "We believe that our agreement with Xinhua will enable us to create a revenue stream as we develop our vaccine program. We are pleased to be able to offer Xinhua surgical instruments to potential U.S. customers. Xinhua surgical instruments are manufactured with German technology and expertise, giving them competitive advantages in product surface, corrosion resistance, performance, as well as price. We believe our knowledge of the Chinese and American medical market should allow us to be effective in introducing the products in the United States." About the Company Bio-Bridge Science, Inc. is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. in Beijing, Bio-Bridge is developing a HIV Vaccine, that is expected to enter clinical trials early next year in China. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Stritch School of Medicine This article or section has multiple issues: * It does not cite any references or sources. Please help improve this article by citing reliable sources. * Its notability is in question. If notability cannot be established, this article may be listed for deletion. , is designed to target infection in mucosal tissues, the first type of tissue attacked by HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. . For more information, call 630/928-0869 or visit http://www.bio-bridge-science. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion